225 related articles for article (PubMed ID: 34668850)
1.
Litvinov V; Makarova M; Kudlay D; Nikolenko N; Mikhailova J
J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34668850
[No Abstract] [Full Text] [Related]
2. Bedaquiline susceptibility testing of Mycobacterium abscessus complex and Mycobacterium avium complex: A meta-analysis study.
Wang M; Men P; Zhang W; Wu J; Gu Y; Wang F; Huang H; Yu X; Duan H
J Glob Antimicrob Resist; 2024 Jun; 37():135-140. PubMed ID: 38561143
[TBL] [Abstract][Full Text] [Related]
3. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
4.
Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.
Brown-Elliott BA; Philley JV; Griffith DE; Thakkar F; Wallace RJ
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872065
[TBL] [Abstract][Full Text] [Related]
6. Difference in drug susceptibility distribution and clinical characteristics between
Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
[No Abstract] [Full Text] [Related]
7. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
[TBL] [Abstract][Full Text] [Related]
8. Comparing the Genotype and Drug Susceptibilities between Mycobacterium avium and Mycobacterium intracellulare in China.
Zheng HW; Pang Y; He GX; Song YY; Zhao YL
Biomed Environ Sci; 2017 Jul; 30(7):517-525. PubMed ID: 28756811
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.
Martin A; Godino IT; Aguilar-Ayala DA; Mathys V; Lounis N; Villalobos HR
J Med Microbiol; 2019 Aug; 68(8):1137-1139. PubMed ID: 31210631
[TBL] [Abstract][Full Text] [Related]
10.
Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China.
Zhao X; Wang Y; Pang Y
Infect Genet Evol; 2014 Oct; 27():332-8. PubMed ID: 25131955
[TBL] [Abstract][Full Text] [Related]
12. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T
J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635
[TBL] [Abstract][Full Text] [Related]
13. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
Fröberg G; Maurer FP; Chryssanthou E; Fernström L; Benmansour H; Boarbi S; Mengshoel AT; Keller PM; Viveiros M; Machado D; Fitzgibbon MM; Mok S; Werngren J; Cirillo DM; Alcaide F; Hyyryläinen HL; Aubry A; Andres S; Nadarajan D; Svensson E; Turnidge J; Giske CG; Kahlmeter G; Cambau E; van Ingen J; Schön T;
Clin Microbiol Infect; 2023 Jun; 29(6):758-764. PubMed ID: 36813087
[TBL] [Abstract][Full Text] [Related]
14. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
[TBL] [Abstract][Full Text] [Related]
15. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex.
Maurer FP; Pohle P; Kernbach M; Sievert D; Hillemann D; Rupp J; Hombach M; Kranzer K
Clin Microbiol Infect; 2019 Mar; 25(3):379.e1-379.e7. PubMed ID: 29906595
[TBL] [Abstract][Full Text] [Related]
16. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
17.
Zhu R; Shang Y; Chen S; Xiao H; Ren R; Wang F; Xue Y; Li L; Li Y; Chu N; Huang H
Microbiol Spectr; 2022 Dec; 10(6):e0137222. PubMed ID: 36250885
[TBL] [Abstract][Full Text] [Related]
18. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China.
Zhang Z; Pang Y; Wang Y; Cohen C; Zhao Y; Liu C
Int J Antimicrob Agents; 2015 May; 45(5):491-5. PubMed ID: 25795316
[TBL] [Abstract][Full Text] [Related]
19. Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease.
Alexander DC; Vasireddy R; Vasireddy S; Philley JV; Brown-Elliott BA; Perry BJ; Griffith DE; Benwill JL; Cameron AD; Wallace RJ
J Clin Microbiol; 2017 Feb; 55(2):574-584. PubMed ID: 27927925
[TBL] [Abstract][Full Text] [Related]
20. Nationwide analysis of Mycobacterium chimaera and Mycobacterium intracellulare isolates: Frequency, clinical importance, and molecular and phenotypic resistance profiles.
Truden S; Žolnir-Dovč M; Sodja E; Starčič Erjavec M
Infect Genet Evol; 2020 Aug; 82():104311. PubMed ID: 32247868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
